Advanced Search

 

Study ID Status Title Patient Level Data
208109/232 Completed Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age Study Listed on ClinicalStudyDataRequest.com
208127/ 114 Completed A phase II, open, randomised, multicentric study to compare the immunogenicity, reactogenicity and safety of experimental vaccines to that of Twinrix (administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years. Study Listed on ClinicalStudyDataRequest.com
208127/076 Completed An open study to evaluate the immunogenicity, safety, and reactogenicity of SmithKline Beecham Biologicals’ commercially available combined hepatitis A/hepatitis B vaccine containing 720 ELISA units of hepatitis A antigen and 20 mcg of hepatitis B surface antigen, administered following a 2 dose schedule in healthy children
208127/091 Completed A phase IV, open, randomized, controlled, comparative, multicenter U.S. study of the safety of GSK Biologicals' combination hepatitis A and hepatitis B vaccine administered on a 0-1-6 mth schedule by intramuscular injection compared with concurrently administered monovalent vaccines in healthy adults Study Listed on ClinicalStudyDataRequest.com
208127/097 Completed An open, randomized, monocentric study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' combined hepatitis A/hepatitis B vaccine compared to separate vaccinations with hepatitis A and hepatitis B vaccines of Chiron Behring/Aventis Pasteur in healthy adult volunteers Study Listed on ClinicalStudyDataRequest.com
208127/098 Completed Comparison of the immunogenicity and safety in healthy monozygotic and dizygotic twins, which have been grown up in the same environment, after having receipt three vaccinations (Months 0-1-6) with the hepatitis A and B combination vaccine TWINRIX™ ADULT Study Listed on ClinicalStudyDataRequest.com
208127/100 and 208127/101 (Ext-HAB-075) Completed A double-blind study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ high-dose combined hepatitis A/B vaccine containing 1440 EL.U of hepatitis A antigen/40 mcg of hepatitis B surface antigen to that of Twinrix™, both administered following a 0-6 month schedule in healthy adolescents Study Listed on ClinicalStudyDataRequest.com
208127/118 Completed A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline (GSK) Biologicals' combined hepatitis A / hepatitis B vaccine in healthy adult volunteers.
208127/120 Completed A phase III, open, randomized, multicenter, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Biologicals’ combined hepatitis A/hepatitis B vaccine administered according to a 0-6 month schedule by intramuscular injection versus TWINRIX™ JUNIOR administered in healthy children Study Listed on ClinicalStudyDataRequest.com
208127/122 Completed An open study to evaluate the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A / hepatitis B vaccine (schedule 0, 1, 6 months) in healthy children aged 1 to 6 years. Study Listed on ClinicalStudyDataRequest.com
208127/123 Completed A phase III open study to assess the anamnestic response to a single injection of Twinrix vaccine, given approximately 44 months after primary vaccination with combined hepatitis A/ hepatitis B vaccine, in healthy subjects who have a previously documented seroprotective anti-HBs antibody response Study Listed on ClinicalStudyDataRequest.com
208127/125 Completed A double-blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' combined hepatitis A / hepatitis B vaccine in healthy children between 6 and 15 years of age. Study Listed on ClinicalStudyDataRequest.com
208127/126 Completed A phase II, open, randomized, multicentric study to evaluate the immunogenicity, reactogenicity and safety of an experimental vaccine to that of Twinrix™ Adult administered following an accelerated schedule (0-7-21 days + 12 months) in healthy adults aged more than 16 years. Study Listed on ClinicalStudyDataRequest.com
208127/127 Completed An open, multicentric, post-marketing surveillance study of GlaxoSmithKline Biologicals’ combined hepatitis A-hepatitis B vaccine (Twinrix™), injected as a three dose primary vaccination course according to the prescribing information, in healthy children and adults.
208127/129 Completed A phase III, double-blind, controlled, multicentric randomized study, designed to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vaccine as compared to the combined hepatitis A/hepatitis B vaccine with preservative, administered according to a 3-dose schedule (0, 1, 6 months) to healthy adults aged 18 years or older
208127/130 Completed A phase IV open study to assess the persistence of anti-HBs and anti-HAV antibodies in older adults approximately 2 years after a primary 3-dose vaccination course with GlaxoSmithKline Biologicals’ combined hepatitis A/hepatitis B vaccine Twinrix™ (720/20) Study Listed on ClinicalStudyDataRequest.com
208127/132 (EXT Y2) Completed Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose Study Listed on ClinicalStudyDataRequest.com
208129/032 Completed A phase III, clinical trial comparing the immunogenicity and safety of SmithKline Beecham Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix™-B, in pre-haemodialysis/haemodialysis patients (>=15 years of age) Study Listed on ClinicalStudyDataRequest.com
208133/161 Completed A controlled clinical study to assess the immunogenicity and reactogenicity of SmithKline Beecham Biologicals varicella vaccine in children aged between 1 and 12 years with a known history of neurodermatitis. SmithKline Beecham Biologicals is currently GlaxoSmithKline Biologicals. Study Listed on ClinicalStudyDataRequest.com
208133/178 Completed A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older. Study Listed on ClinicalStudyDataRequest.com
208136/006 Completed A phase II, open, randomized, multicentre study evaluating in healthy children 12-24 months of age, the safety and immunogenicity of GlaxoSmithKline Biologicals' combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA), compared to GlaxoSmithKline Biologicals' Varicella vaccine Study Listed on ClinicalStudyDataRequest.com
208136/007 Completed Study to assess consistency of 3 production lots of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Biologicals’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life Study Listed on ClinicalStudyDataRequest.com
208136/013 Completed Study to assess immunogenicity and safety of one dose of GSK Biologicals’ live attenuated MMRV vaccine, co-administered with a booster dose of the GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine Study Listed on ClinicalStudyDataRequest.com
208136/014 Completed Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella Study Listed on ClinicalStudyDataRequest.com
208136/016 Completed Study to assess immunogenicity and safety of two lots of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Biologicals’ measles-mumps-rubella vaccine as control group Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.